Legend Biotech is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Co.'s primary product candidate, ciltacabtagene autoleucel, or cilta-cel (referred to as LCAR- B38M for purposes of its LEGEND-2 trial), is a chimeric antigen receptor T cell (CAR-T) therapy it is jointly developing with its partner, Janssen Biotech, Inc. for the treatment of multiple myeloma. In addition to cilta-cel, Co. has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma. The LEGN average annual return since 2020 is shown above.
The Average Annual Return on the LEGN average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether LEGN average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LEGN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|